• breast cancer - adjuvant 13

 

• antibody–drug conjugate
• trastuzumab emtansine
• trastuzumab emtasine plus endocrine therapy
• cyclin inhibitor
• abemaciclib based treatment
• abemaciclib plus endocrine therapy
• palbociclib based treatment
• palbociclib
• palbociclib plus endocrine therapy
• HER inhibitor
• HER2 inhibitor
• neratinib based treatment
• neratinib
• pertuzumab based treatment
• pertuzumab plus trastuzumab
• trastuzumab based treatment
• docetaxel plus carboplatin with trastuzumab followed by trastuzumab
• doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab
• immune chekpoint inhibitors
• anti-PD-(L)1
• pembrolizumab based treatment
• pembrolizumab alone
• mTOR inhibitors
• everolimus
• poly ADP-ribose polymerase (PARP) inhibitor
• olaparib

• versus all
• vs chemotherapy
• vs doxorubicin plus cyclophosphamide followed by docetaxel
• vs endocrine therapy
• vs HER inhibitor
• vs HER2 inhibitor
• vs trastuzumab based treatment
• vs docetaxel plus carboplatin with trastuzumab followed by trastuzumab
• vs trastuzumab
• vs non active control
• vs placebo

  All patients

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

breast cancer - adjuvant, pembrolizumab based treatment vs. all, meta-analysis of study results

No data for this selection

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;